Preoperative radiochemotherapy for rectal cancer: Forecasting the next steps through ongoing and forthcoming studies;Chimioradiothérapie préopératoire des cancers du rectum : ce que laissent présager les études en cours et à venir

Cancer/Radiotherapie

Volumn 15, Issue 6-7, 2011, Pages 440-444

  Crehange G ^a   Bosset, J F ^b   Maingon, P ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Adjuvant chemotherapy; Ongoing studies; Preoperative chemotherapy; Preoperative radiotherapy; Rectal cancer; Surgery

Indexed keywords

FLUOROURACIL;

CANCER ADJUVANT THERAPY; CANCER STAGING; DISTANT METASTASIS; HUMAN; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIOSENSITIZATION; RECTUM CANCER; RECURRENCE RISK; REPRODUCIBILITY; SHORT SURVEY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; FORECASTING; HUMANS; LEUCOVORIN; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053302871     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.05.006     Document Type: Short Survey

References (31)

1. Bosset J.F., Collette L., Calais G., Mineur L., Maingon P., Radosevic-Jelic L., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
2. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., Putter H., Steup W.H., Wiggers T., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
3. Peeters K.C., Marijnen C.A., Nagtegaal I.D., Kranenbarg E.K., Putter H., Wiggers T., et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007, 246:693-701.
4. Folkesson J., Birgisson H., Pahlman L., Cedermark B., Glimelius B., Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005, 23:5644-5650.
5. Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Swedish Rectal Cancer Trial. Eur J Surg 1996;162:397-402.
6. Sauer R., Becker H., Hohenberger W., Rödel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
7. Martling A., Holm T., Johansson H., Rutqvist L.E., Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 2001, 92:896-902. Stockholm Colorectal Cancer Study Group.
8. Cedermark B., Johansson H., Rutqvist L.E., Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1995, 75:2269-2275. Stockholm Colorectal Cancer Study Group.
9. Brændengen M., Tveit K.M., Bruheim K., Cvancarova M., Berglund A., Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in non resectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys 2010, doi:10.1016/j.ijrobp.2010.07.007.
10. Birgisson H., Påhlman L., Gunnarsson U., Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005, 23:8697-8705. Swedish Rectal Cancer Trial Group.
11. Tiv M., Puyraveau M., Mineur L., Calais G., Maingon P., Bardet E., et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radioth 2010, 14:530-534.
12. Peeters K.C., van de Velde C.J., Leer J.W., Martijn H., Junggeburt J.M., Kranenbarg E.K., et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol 2005, 23:6199-6206.
13. Gray R., Barnwell J., McConkey C., Hills R.K., Williams N.S. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. Quasar Collaborative Group.
14. Collette L., Bosset J.F., den Dulk M., Nguyen F., Mineur L., Maingon P., et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radio-chemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007, 25:4379-4386.
15. Everaert H., Hoorens A., Vanhove C., Sermeus A., Ceulemans G., Engels B., et al. Prediction of response to neoadjuvant radiotherapy in patients with locally advanced rectal cancer by means of sequential 18FDG-PET. Int J Radiat Oncol Biol Phys 2011, 80:91-96.
16. De Ridder M., Tournel K., Van Nieuwenhove Y., Engels B., Hoorens A., Everaert H., et al. Phase II study of preoperative helical tomotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70:728-734.
17. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
18. Pettersson D., Cedermark B., Holm T., Radu C., Påhlman L., Glimelius B., et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010, 97:580-587.
19. Siegel R., Burock S., Wernecke K.D., Kretzschmar A., Dietel M., Loy V., et al. Preoperative short-course radiotherapy versus combined radio-chemotherapy in locally advanced rectal cancer: a multicentre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009, 9:50.
20. Gérard J.P., Azria D., Gourgou-Bourgade S., Martel-Laffay I., Hennequin C., Etienne P.L., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28:1638-1644.
21. Aschele C., Pinto C., Cordio S., Rosati G., Tagliagambe A., Artale S., et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial 2009 ASCO Annual Meeting. J Clin Oncol 2009, 27. [suppl.; abstr CRA4008].
22. Mitchell E.P. Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer. Oncology (Williston Park) 2000, 14:56-59.
23. Mehta V.K., Cho C., Ford J.M., Jambalos C., Poen J., Koong A., et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003, 55:132-137.
24. Dipetrillo T., Pricolo V., Lagares-Garcia J., Vrees M., Klipfel A., Cataldo T., et al. Neoadjuvant bevacizumab oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2010, doi:10.1016/j.ijrobp.2010.08.005.
25. Willett C.G., Duda D.G., Ancukiewicz M., Shah M., Czito B.G., Bentley R., et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010, 15:845-851.
26. Crane C.H., Eng C., Feig B.W., Das P., Skibber J.M., Chang G.J., et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010, 76:824-830.
27. Nogué M., Salud A., Vicente P., Arriví A., Roca J.M., Losa F., et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS Study. Oncologist 2011, doi:10.1634/theoncologist.2010-0285.
28. Fernández-Martos C., Pericay C., Aparicio J., Salud A., Safont M., Massuti B., et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010, 28:859-865.
29. Gérard J.P., Rostom Y., Gal J., Benchimol D., Ortholan C., Aschele C., et al. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials. Crit Rev Oncol Hematol 2011, doi:10.1016/j.critrevonc.2011.02.001.
30. Braendengen M., Tveit K.M., Berglund A., Birkemeyer E., Frykholm G., Påhlman L., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26:3687-3694.
31. Tournat H., Vendrely V., Cherciu B., Smith D., Laurent C., Capdepont M., et al. Intérêt de la radiothérapie dans le traitement de la tumeur primitive rectale lorsque sont associées des métastases synchrones. Cancer Radiother 2008, 12:336-342.